Future therapy for non‐alcoholic fatty liver disease


Non‐alcoholic fatty liver disease is a leading cause of chronic liver disease and can lead to cirrhosis, hepatocellular cancer and end stage liver disease. It is also associated with increased cardiovascular and cancer related morbidity and mortality. The pathogenesis of non‐alcoholic fatty liver disease includes metabolic stress to the liver associated with insulin resistance with downstream cell stress from reactive oxygen species and unfolded protein response with activation of inflammatory and fibrotic pathways. There are currently no approved therapies for non‐alcoholic fatty liver disease. This review summarizes ongoing efforts to establish the treatment of non‐alcoholic steatohepatitis the progressive form of non‐alcoholic fatty liver disease. Therapies are currently directed towards improving the metabolic status of the liver, cell stress, apoptosis, inflammation or fibrosis. Several agents are now in pivotal trials and it is expected that the first therapies will be approved in 2‐3 years.


cirrhosis, fibrosis, nonalcoholic fatty liver disease, nonalcoholic fatty liver disease activity score, nonalcoholic steatohepatitis


About Speaker


Professor of Medicine


City: Richmond

Institution: Virginia Commonwealth University

Contact: arun.sanyal@vcuhealth.org

Biography of Arun SANYAL

Dr. Sanyal is a specialist in chronic liver disease and its outcomes. He is the Executive Director, Education Core, Clinical Center for Translational Research, VCU. He served as a chair of the National Institutes of Health (NIH) NASH Research Network and is the current Chair of the Liver Study Section at NIH. He is the Academic and Steering Committee Co-Chair of The Liver Forum. His research into liver diseases has led to recommendations related to variceal hemorrhage, ascites, hepatorenal syndrome, hepatic encephalopathy, and NASH. He is the American Liver Foundation 2017 Distinguished Scientific Award Winner Recipient.

View more